Symbio Pharmaceuticals Limited (JP:4582)
:4582
Want to see JP:4582 full AI Analyst Report?
4582 Stock Chart & Stats
¥90.00
¥6.00(2.96%)
At close: 4:00 PM EST
¥90.00
¥6.00(2.96%)
Day’s Range― - ―
52-Week Range¥81.00 - ¥229.00
Previous CloseN/A
Volume447.50K
Average Volume (3M)577.10K
Market Cap
¥6.82B
Enterprise Value¥3.70B
Total Cash (Recent Filing)¥3.05B
Total Debt (Recent Filing)¥1.30B
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-100.12
Shares Outstanding77,628,910
10 Day Avg. Volume434,010
30 Day Avg. Volume577,100
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)3.55
Price to Sales (P/S)3.46
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustainably high gross margins indicate structural product-level pricing power and efficient production. If the company can rein in SG&A and R&D spend or scale sales, those margins provide a durable pathway to profitability and cash generation once revenues stabilize or recover.
Licensing/partner Commercialization ModelA licensing and partnership-driven model reduces direct early‑stage R&D expense and spreads development risk. Milestones and royalties create potential non-linear cash inflows as products advance, offering a durable, capital-efficient route to revenue diversification over time.
Focus On Specialty Oncology And HematologyConcentrating on specialty oncology/hematology targets higher unmet-need segments with durable demand and pricing resilience. Success in these niches can secure long-term market niches, stronger margins, and differentiated competitive positioning versus commoditized therapies.
Bears Say
Multi-year Revenue And Margin DeteriorationSustained revenue declines and a multi-year switch to deep negative margins indicate structural business deterioration rather than a transient setback. This reduces reinvestment capacity, undermines partner confidence, and makes a durable operational turnaround more challenging without clear revenue recovery.
Meaningful Negative Operating And Free Cash FlowPersistent negative operating cash flow forces reliance on external financing or asset monetization, which can dilute shareholders or increase leverage. It constrains the firm’s ability to fund launches, trials, or commercialization activities, threatening long-term viability if losses continue.
New Debt And Compressed Equity BaseRecent leverage after years of no debt raises fixed obligations and financial risk amid ongoing losses. A debt-to-equity above 1 and a shrinking equity base reduce financial flexibility, increase default risk, and limit the company’s ability to absorb commercialization or regulatory delays.
Symbio Pharmaceuticals Limited News
4582 FAQ
What was Symbio Pharmaceuticals Limited’s price range in the past 12 months?
Symbio Pharmaceuticals Limited lowest stock price was ¥81.00 and its highest was ¥229.00 in the past 12 months.
What is Symbio Pharmaceuticals Limited’s market cap?
Symbio Pharmaceuticals Limited’s market cap is ¥6.82B.
When is Symbio Pharmaceuticals Limited’s upcoming earnings report date?
Symbio Pharmaceuticals Limited’s upcoming earnings report date is Jul 30, 2026 which is in 77 days.
How were Symbio Pharmaceuticals Limited’s earnings last quarter?
Symbio Pharmaceuticals Limited released its earnings results on May 07, 2026. The company reported -¥35.89 earnings per share for the quarter, missing the consensus estimate of N/A by -¥35.89.
Is Symbio Pharmaceuticals Limited overvalued?
According to Wall Street analysts Symbio Pharmaceuticals Limited’s price is currently Overvalued.
Does Symbio Pharmaceuticals Limited pay dividends?
Symbio Pharmaceuticals Limited does not currently pay dividends.
What is Symbio Pharmaceuticals Limited’s EPS estimate?
Symbio Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Symbio Pharmaceuticals Limited have?
Symbio Pharmaceuticals Limited has 77,628,910 shares outstanding.
What happened to Symbio Pharmaceuticals Limited’s price movement after its last earnings report?
Symbio Pharmaceuticals Limited reported an EPS of -¥35.89 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Symbio Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in JP:4582
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Symbio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.
Technical Analysis
Solasia Pharma KK
―
Wakamoto Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Medrx Co., Ltd.
―